Amgen Inc. Files SEC Form 4 Disclosure

Strategic Insights -

Biotech giant Amgen Inc. filed a critical disclosure on August 12, 2022, with the Securities and Exchange Commission (SEC) under Form 4. The filing reveals key information about the company's executive officers and stock ownership. As a leading biopharmaceutical company, Amgen's disclosure is closely watched by investors and industry observers.

Key Takeaways:

  • Amgen Inc. filed Form 4 on August 12, 2022, disclosing SEC filing 0001127602-22-020890.
  • The filing revealed that one document was submitted, with the SEC file number listed as 0001127602-22-020890.
  • The contact information for Amgen Inc. is listed as ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320, with a phone number of (805)447-1000.
  • Form 4 disclosures are required for directors, officers, or owners of more than 10% of a class of equity securities registered under Section 12 of the '34 Act.
  • The form includes information on the reporting person's relationship to the company and on purchases and sales of equity securities.
  • Amgen's filing is a submission to the SEC, providing a formal document or financial statement to the public record.

Statistics:

  • One document was filed with the SEC, with a filing date of August 12, 2022 (0001127602-22-020890).
  • The SIC code for Amgen Inc. is 2836, Biological Products.
  • The contact information for Amgen Inc. includes a physical address in Thousand Oaks, CA, and a phone number.
  • Amgen Inc. is a biopharmaceutical company with a significant market presence.

Sources:

  • U.S. Securities and Exchange Commission (SEC)
  • Amgen Inc.(Form 4)
  • News Reporter-Staff News Editor at Biotech Week